Drug intelligence / Profile preview

Emollivet COMBI

Development stage: Unknown
Lead developer: Emollivet
Modality: Small Molecules
Administration: Topical

Overview

Emollivet COMBI is a veterinary topical antiseptic emollient spray developed by Emollivet AB, a subsidiary of Lipidor, for the treatment of equine pastern dermatitis in horses, including mud fever, greasy heel, cracked heel, scratches, and scabies. It is an alcohol-based lipid spray formulated with Lipidor's AKVANO lipid-based technology and Aurena bag-on-valve spray technology, and contains salicylic acid, chlorhexidine, and soybean-derived lipids. The product is designed to provide triple-action local therapy by keratolytically exfoliating hyperkeratotic or crusted skin, reducing microbial burden through antiseptic activity, and softening or restoring the skin barrier through emollient lipids, enabling easy once-daily or repeated topical application without rinsing.

Brand names: Emollivet COMBI

Beyond the preview

Go deeper on Emollivet COMBI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emollivet COMBI.

Explore the full profile